| Conţinutul numărului revistei |
| Articolul precedent |
| Articolul urmator |
 |
 668 1 |
| Ultima descărcare din IBN: 2023-05-03 12:05 |
 SM ISO690:2012DUMBRAVA, Vlada-Tatiana, , , , , , , , , COJUHARI, Maria, DELI, M.. Evaluarea tratamentului antiviral la pacienţii cu ciroze hepatice de etiologie virală C şi D. In: Sănătate Publică, Economie şi Management în Medicină , 2013, nr. 5(50), pp. 118-122. ISSN 1729-8687. |
| EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
| Sănătate Publică, Economie şi Management în Medicină | ||||||
| Numărul 5(50) / 2013 / ISSN 1729-8687 /ISSNe 2587-3873 | ||||||
|
||||||
| Pag. 118-122 | ||||||
|
||||||
 Descarcă PDF |
||||||
| Rezumat | ||||||
Study group: 49 patients, 17 (34.69%) women and 32 (65.31%) men with hepatic viral cirrhosis, Child-Pugh stage A: 24 – D viral etiology and 25 – viral C genesis. Average age: 44.41 ± 0.4 years in women and 47.59 ± 0.6 years in men. Purpose: evaluation of the antiviral treatment response at 12 weeks and 24 weeks after initiation and assessment of laboratory results during antiviral therapy in patients with liver cirrhosis C and D. In patients with liver cirrhosis HDV, treated with Peg-INF undetectable viral load was achieved at 12 weeks in 28% cases and after 24 weeks of treatment it is observed in 25% cases. In the group of patients with liver cirrhosis HCV, treated with Peg-INF + Ribabirină – 12 weeks of treatment – 75% of patients responded positively: 48% achieved complete EVR and 24% – EVR part. Evaluation of patients at 24 weeks of treatment show a positive virologic response in 56% cases. In patients with liver cirrhosis HCV and HDV, where the virological response was absent, more severe and early complications of antiviral therapy are observed: the blood count shows anemia, major leukopenia and thrombocytopenia. |
||||||
| Cuvinte-cheie liver cirrhosis, antiviral treatment, sustained virological response, unidentifi ed viremia, цирроз печени, противовирусное лечение, вирусологический ответ, авиремия |
||||||
|
DataCite XML Export
<?xml version='1.0' encoding='utf-8'?> <resource xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns='http://datacite.org/schema/kernel-3' xsi:schemaLocation='http://datacite.org/schema/kernel-3 http://schema.datacite.org/meta/kernel-3/metadata.xsd'> <creators> <creator> <creatorName>Dumbrava, V.A.</creatorName> <affiliation>Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Лупашко, ..</creatorName> <affiliation>Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Таран, .</creatorName> <affiliation>Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Тофан-Скутару, .</creatorName> <affiliation>Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Тофан-Скутару, .</creatorName> <affiliation>Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Cojuhari, M.</creatorName> <affiliation>IMSP Spitalul Clinic Republican „Timofei Moșneaga”, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Deli, M.</creatorName> <affiliation>Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“, Moldova, Republica</affiliation> </creator> </creators> <titles> <title xml:lang='ro'>Evaluarea tratamentului antiviral la pacienţii cu ciroze hepatice de etiologie virală C şi D</title> </titles> <publisher>Instrumentul Bibliometric National</publisher> <publicationYear>2013</publicationYear> <relatedIdentifier relatedIdentifierType='ISSN' relationType='IsPartOf'>1729-8687</relatedIdentifier> <subjects> <subject>liver cirrhosis</subject> <subject>antiviral treatment</subject> <subject>sustained virological response</subject> <subject>unidentifi ed viremia</subject> <subject>цирроз печени</subject> <subject>противовирусное лечение</subject> <subject>вирусологический ответ</subject> <subject>авиремия</subject> </subjects> <dates> <date dateType='Issued'>2013-10-01</date> </dates> <resourceType resourceTypeGeneral='Text'>Journal article</resourceType> <descriptions> <description xml:lang='en' descriptionType='Abstract'><p>Study group: 49 patients, 17 (34.69%) women and 32 (65.31%) men with hepatic viral cirrhosis, Child-Pugh stage A: 24 – D viral etiology and 25 – viral C genesis. Average age: 44.41 ± 0.4 years in women and 47.59 ± 0.6 years in men. Purpose: evaluation of the antiviral treatment response at 12 weeks and 24 weeks after initiation and assessment of laboratory results during antiviral therapy in patients with liver cirrhosis C and D. In patients with liver cirrhosis HDV, treated with Peg-INF undetectable viral load was achieved at 12 weeks in 28% cases and after 24 weeks of treatment it is observed in 25% cases. In the group of patients with liver cirrhosis HCV, treated with Peg-INF + Ribabirină – 12 weeks of treatment – 75% of patients responded positively: 48% achieved complete EVR and 24% – EVR part. Evaluation of patients at 24 weeks of treatment show a positive virologic response in 56% cases. In patients with liver cirrhosis HCV and HDV, where the virological response was absent, more severe and early complications of antiviral therapy are observed: the blood count shows anemia, major leukopenia and thrombocytopenia.</p></description> <description xml:lang='ru' descriptionType='Abstract'><p>Группа исследования: 49 пациентов, 17 (34,69%) женщин и 32 (65,31%) мужчин с циррозом печени вирусной этиологии, стадия Child-Pugh А: 24 – вирусной этиологии D и 25 – вирусной этиологии C. Средний возраст: 44,41 ± 0,4 лет у женщин и 47,59 ± 0,6 лет у мужчин. Цель: оценка ответа на противовирусное лечение на 12-ой неделе и на 24-ой неделе после начала лечения и оценка лабораторных показателей во время противовирусной терапии у больных с циррозом печени С или D. У пациентов с циррозом печени HDV, леченных Peg-INF, была достигнута авиремия на 12-ой неделе в 28% случаев и на 24-ой неделе лечения – в 25% случаев. В группе пациентов с циррозом печени вирусной этиологии С, леченных Peg-INF + рибавирин, наблюдается на 12-ой неделе лечения положительный ответ у 75% пациентов: 48% достигнули полный ранний вирусологический ответ, 24% – частичный. Оценка противовирусного лечения через 24 недели после начала показала положительный вирусологический ответ в 56% случаев. У пациентов с циррозом печени вирусой этиологии С или D с отсутствием вирусологического ответа на противирусную терапию обнаруживаются осложнения более тяжелые и раньше: в анализе крови – анемия, лейкопения и тромбоцитопения.</p></description> </descriptions> <formats> <format>application/pdf</format> </formats> </resource>
|
|
|
